Otsuka received the 2019 Corporate Innovator Award from the National Kidney Foundation (NKF) at the NKF 2019 Spring Clinical Meetings in Boston during May.

The Corporate Innovator Award was established to recognize companies that advance the field of nephrology by addressing an unmet medical need, or improving upon an existing practice, therapeutic or technology. Otsuka Pharmaceutical received this award in recognition for its work in bringing JYNARQUE^TM (tolvaptan) to market.

Kevin Longino, the CEO of National Kidney Foundation who is also a kidney transplant recipient, noted, "The Corporate Innovator Award recognizes Otsuka's significant contribution to improving the lives of people with ADPKD and we congratulate them on this achievement."

The award was accepted on behalf of Otsuka by Louis Allesandrine, Vice President, Oncology and Nephrology Sales and Marketing at Otsuka America Pharmaceutical, Inc. He commented during the award presentation, "It is an honor and a privilege to accept this award on the behalf of the many people who made this possible, including patients, families, researchers, nephrologists, and Otsuka."

For additional information on the award granted to Otsuka, please refer to the NKF's press release:

• https://www.kidney.org/news/nkf-honors-otsuka-pharmaceutical-company-ltd-scm19-corporate-innovator-award

In April 2018, JYNARQUE^TM was approved by the U.S. Food and Drug Administration as the first treatment to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Earlier, the drug was approved for use in the EU, Japan and several other countries.

The National Kidney Foundation is the largest, most comprehensive and longstanding organization in the U.S. dedicated to the awareness, prevention and treatment of kidney disease.